Brezosiran Deep mHTT Cut Masks Thin Clinical Proof Ahead of 2027 Pivotal

Alnylam Advances Brezosiran to Pivotal Trial for Huntington's Disease

Alnylam Pharmaceuticals is advancing its Huntington's disease drug, brezosiran (formerly ALN-HTT02), into a placebo-controlled pivotal study in 2027, following promising Phase 1b clinical trial results. The RNAi therapeutic demonstrated robust and dose-dependent reductions in mutant huntingtin protein (mHTT) in the cerebrospinal fluid, with a mean reduction of 60%-64% at three months in the highest dose group, and a peak reduction of 83%. This early readout suggests a potential multibillion-dollar market opportunity for Alnylam in a disease with significant unmet needs.

• In the ongoing Phase 1b trial, brezosiran achieved significant reductions in mutant huntingtin protein (mHTT) in the cerebrospinal fluid. The highest dose group showed a mean reduction of 60%–64% at three months, with an observed maximum reduction of 83%. These dose-dependent results were confirmed by two independent assays, indicating strong target engagement.
• Encouraged by the early data, Alnylam plans to move brezosiran into a placebo-controlled pivotal trial in 2027, pending regulatory alignment. The observed durability of mHTT-lowering also suggests the potential for a convenient twice-yearly dosing paradigm in future development, which could enhance patient adherence and market appeal.
• Analysts project a multibillion-dollar opportunity for Alnylam in Huntington's disease due to the severity of the condition and the lack of effective treatments. Brezosiran, developed with Regeneron, targets exon 1 of the HTT mRNA transcript, aiming to reduce all forms of the protein, differentiating it from other candidates like Roche's tominersen, which failed despite similar mHTT lowering.

Addressing Critical Gaps in Huntington's Disease Treatment

Current treatment approaches for Huntington's disease remain largely symptomatic and challenging, consisting mainly of off-label treatments. Data support only the use of VMAT2 inhibitors for specific motor symptoms, and the data did not support a disease-modifying effect for premanifest and manifest HD.

• Limited efficacy and tolerability of approved chorea therapies. Tetrabenazine reduces chorea, on average, by 5 units based upon the chorea score from the Unified Huntington's Disease Rating Scale, and deutetrabenazine showed reductions in chorea persisted over time. Both are associated with somnolence, depression, anxiety, insomnia, akathisia, parkinsonism and suicidality, with tetrabenazine also carrying a black box warning for increasing the risk of depression and suicidality. Tolerability limits dosing: 51% of physicians agree that they are unable to titrate to efficacious doses due to adverse side effects or tolerability concerns, and documented treatment discontinuation due to adverse effects was less frequent in tiapride courses than in tetrabenazine courses (27% vs 55%; P = 0.005).

• No supported treatments for neuropsychiatric symptoms and non-pharmacologic care. There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality, and no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments. Individuals with HD who present with irritability may be managed with a variety of psychotropic medications, primarily antidepressants and antipsychotics, while antipsychotics were used in 61.6% of nursing home residents with HD and anxiolytics were received by 59.1% of residents.

• Risks of non-selective huntingtin-lowering and uncertainty in disease-modification. Several clinical trials are exploring HTT-lowering approaches that target both wt-HTT and the mutant isoform responsible for Huntington's disease, yet network synchronization defects only became apparent when more than two-thirds of the wt-HTT protein was depleted. Interventions to limit somatic repeat expansion might be effective when combined with huntingtin lowering, but determining the optimal point for therapeutic intervention and how best to establish phenotypic improvement in clinical trials when the target tissue is the brain poses challenges.

• Biomarker and monitoring gaps linked to psychiatric risk and late-stage care. Mutant huntingtin and somatic expansion ratio provide mechanistic evidence of target engagement, but HD-YAS showed SER predicts striatal atrophy over multi-year intervals, but its short-term sensitivity remains uncertain. Moving toward qualified endpoints will require harmonised methods, improved analytical validation and stronger evidence linking biomarker change to clinical benefit. Psychiatric comorbidities predict suicidal behavior, with depressed mood at baseline the only independent predictor of suicidality at follow-up (OR=10.6), while only one study reported use of palliative care services (4%).

Brezosiran's Biomarker-Driven Approach to Huntington's

The knowledge base does not have sufficient information to answer this question.

Navigating the Evolving Huntington's Disease Treatment Landscape

Symptomatic management of Huntington's disease (HD) chorea remains centered on vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine, deutetrabenazine, and valbenazine. In KINECT-HD (NCT04102579), a phase 3, randomised, double-blind, placebo-controlled trial in 46 Huntington Study Group sites in the USA and Canada, least-squares mean changes in Unified Huntington's Disease Rating Scale Total Maximal Chorea score were -4·6 for valbenazine and -1·4 for placebo (least-squares mean difference -3·2, 95% CI -4·4 to -2·0; p<0·0001), with somnolence in ten [16%] with valbenazine and two [3%] with placebo. A meta-analysis of seven randomized trials (1431 participants) reported VMAT 2 inhibitors significantly improved motor outcomes versus placebo (UHDRS TMS: MD -3.80, 95% CI -5.76 to -1.83; TMC: MD -3.05, 95% CI -3.84 to -2.26; both I = 0%), while dopamine stabilizers produced no meaningful change (UHDRS TMS: MD -0.98, 95% CI -2.48 to 0.51; I = 32%). A 25-year retrospective single-center analysis of 140 adults with genetically confirmed HD found tiapride more frequently used as first-line therapy (69% vs 31%) with documented treatment discontinuation due to adverse effects less frequent in tiapride courses than in tetrabenazine courses (27% vs 55%; P = 0.005), and a dual-site retrospective cohort of 30 patients on deutetrabenazine >48 mg daily reported median total maximum chorea score of 13 (IQR 9-19) at baseline and 13 (IQR 7-18) at follow-up with median proportion of days covered of 0.99 (IQR 0.94-1.00).

Disease-modifying development has focused on mutant huntingtin (HTT)-lowering with antisense oligonucleotides (ASO), splicing modulators, microRNA molecules and gene therapy, without an approved disease-modifying therapy. A trial on tominersen, an antisense oligonucleotide designed to reduce the production of the huntingtin protein, was prematurely interrupted because the drug failed to show higher efficacy than placebo and, at highest doses, led to worsened outcomes, following initial negative results with Tominersen and WVE-120101/ WVE-120102. In VIBRANT-HD, a randomized phase 2b study of the orally available HTT messenger RNA splicing modulator branaplam (ClinicalTrials.gov identifier: NCT05111249), 18 (85.7%) of 21 participants receiving branaplam 56 mg weekly showed at least one sign or symptom of peripheral neuropathy, triggering early termination, with increased neurofilament light chain levels in most participants reversing after discontinuation. Preclinical work supports allele-selective lowering via stereopure oligonucleotides targeting rs362273 with advancement of WVE-003 (NCT05032196), while a Phase II randomized, double-blind, placebo-controlled trial of intravenous human dental pulp stem cell therapy NestaCell in 35 patients reported both doses significantly improved UHDRS-TMS compared to placebo (p = 0.005), with the 2 million cells/kg group showing significant benefits in UHDRS-TFC (p = 0.011).

Longitudinal and methodologic data have refined interpretation of progression and safety of chronic antidopaminergic use. Using the Enroll-HD database with a new-user design and doubly robust targeted maximum likelihood estimation controlling for 27 covariates, the ADM-exposed group exhibited faster change in measures of clinical outcome compared with the off-ADM group, statistically reliable in cognitive and functional outcome measures and the composite Unified Huntington's Disease Rating Scale (cUHDRS), with faster change in bradykinesia but no difference in chorea or total motor score (TMS), and higher ADM doses showing greater differences. The cUHDRS correlates with imaging biomarkers, with worse performance over time correlating with longitudinal volume decreases in the occipito-parietal cortex and centrum semiovale in 119 premanifest and 119 early-HD participants. Modeling of 8,071 Enroll-HD participants and 260 GENERATION HD1 placebo participants (NCT03761849, NCT01574053) showed Total Functional Capacity aligned with predicted natural history (within 95% CI) while Total Motor Score improved until week 69 then converged at weeks 85 and 101, and Symbol Digit Modalities Test and Stroop Word Reading showed sustained improvement to week 101, and the Roche HD Digital Monitoring Platform showed good to excellent test-retest reliability (intraclass correlation coefficient 0.89-0.98) with completion of 89.95% (1164/1294), 72.01% (2025/2812), and 68.98% (1454/2108) of active tests across cohorts.

Brezosiran's Pivotal Leap: Redefining Huntington's Disease Therapy

The advancement of Alnylam's brezosiran into a pivotal clinical study marks a critical juncture for the Huntington's disease (HD) community. HD is a devastating, inherited neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene, leading to the production of a toxic mutant huntingtin protein (mHTT). With no disease-modifying treatments currently available, patients face progressive motor, cognitive, and psychiatric decline over 15-20 years, highlighting an urgent unmet medical need.

Brezosiran, an RNA interference (RNAi) therapeutic, offers a promising approach by directly targeting the root cause of HD: silencing the HTT gene to reduce mHTT production. The Phase 1b results, demonstrating robust and dose-dependent reductions of mHTT in the cerebrospinal fluid (CSF), are particularly encouraging. This strong pharmacodynamic signal is vital, as mHTT in CSF is a validated biomarker for disease progression and therapeutic response. Such clear evidence of target engagement provides a strong foundation for the upcoming pivotal trial, potentially streamlining its design and offering a compelling narrative for regulatory bodies.

However, the path forward is not without its complexities. A primary challenge will be demonstrating that this significant biomarker reduction translates into tangible clinical benefits, such as slowing the progression of motor, cognitive, and psychiatric symptoms in a patient population known for its clinical heterogeneity. Furthermore, the long-term safety and tolerability of chronic intrathecal administration, including any potential off-target effects or the impact of reducing wild-type huntingtin protein, will be under intense scrutiny. The competitive landscape is also dynamic, with ongoing research into allele-specific RNAi therapies, antisense oligonucleotides (ASOs), and innovative non-invasive delivery methods like focused ultrasound, exosomes, or intranasal nanoparticles. These alternative strategies could offer different risk-benefit profiles or administration advantages in the future. Despite these considerations, brezosiran's progress underscores the transformative potential of RNA-based therapeutics in addressing the underlying molecular mechanisms of neurodegenerative diseases, potentially ushering in a new era of targeted interventions for conditions previously deemed untreatable.